A long-term analysis of 620 patients with malignant melanoma at a major referral center

被引:26
作者
Averbook, BJ
Russo, LJ
Mansour, EG
机构
[1] Case Western Reserve Univ, Metrohlth Med Ctr, Dept Surg, Div Surg Oncol, Cleveland, OH 44109 USA
[2] Case Western Reserve Univ, Metrohlth Med Ctr, Dept Epidemiol & Biostat, Cleveland, OH 44109 USA
关键词
D O I
10.1067/msy.1998.91269
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. A univariate and multivariate statistical analysis of a single surgeon's experience with resectable malignant melanoma during 26 years (November 1970 to August 1996) was conducted. Methods. Six hundred twenty consecutive patients were registered. Univariate analysts of disense-fr ee survival (DFS) and melanoma survival (MS) was calculated by the Kaplan-Meier method and correlated to American Joint Committee on Cancer stage, thickness, ulceration, site, lymph node involvement, age, sex, type, and excision margins. Linear trends, log-rank test, and pairwise comparisons were used to discriminate differences in survival curves. A Cox proportional hazards model was used for multivariate analysis and determination of relative risk. Results. Univariate analysis of stage, thickness (in millimeters), ulceration, lymph node involvement, age, type, and margins of excision were predictive of DFS (5 years, 85.7%; 10 years, 82.5%) and MS (5 years, 92.2%; 10 years, 87.8%) (P < .01). Multivariate analysis revealed correlations with thickness, ulceration, and age in predicting DFS (relative risk = 2.75, 2.21, and 1.47, respectively) and MS (relative risk = 2.66, 2.47, and 1.48, respectively). The 5-year MS rate was 73.3% and 93.3% for patients with positive and negative lymph nodes, respectively. Of 133 patients who underwent lymph node dissection, 28 (21.1%) had nodal metastases. Patients with primary melanomas thicker than 4 mm had 50% metastatic involvement of their lymph nodes. Conclusions. Our findings reveal that thickness, ulceration, and age are the most important predicting factors in DFS and MS. The data support including ulceration and age in modifying America joint Committee on Cancer staging for melanoma.
引用
收藏
页码:746 / 756
页数:11
相关论文
共 24 条
[11]  
MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392
[12]  
MORTON DL, 1993, CANCER-AM CANCER SOC, V71, P3737, DOI 10.1002/1097-0142(19930601)71:11<3737::AID-CNCR2820711143>3.0.CO
[13]  
2-7
[14]   Cancer statistics, 1996 [J].
Parker, SL ;
Tong, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 1996, 46 (01) :5-27
[16]   USE OF TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN THE IMMUNOTHERAPY OF PATIENTS WITH METASTATIC MELANOMA - A PRELIMINARY-REPORT [J].
ROSENBERG, SA ;
PACKARD, BS ;
AEBERSOLD, PM ;
SOLOMON, D ;
TOPALIAN, SL ;
TOY, ST ;
SIMON, P ;
LOTZE, MT ;
YANG, JC ;
SEIPP, CA ;
SIMPSON, C ;
CARTER, C ;
BOCK, S ;
SCHWARTZENTRUBER, D ;
WEI, JP ;
WHITE, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (25) :1676-1680
[17]  
Ross M I, 1991, Adv Surg, V24, P139
[18]   LYMPHADENECTOMY IN THE MANAGEMENT OF STAGE-I MALIGNANT-MELANOMA - A PROSPECTIVE RANDOMIZED STUDY [J].
SIM, FH ;
TAYLOR, WF ;
PRITCHARD, DJ ;
SOULE, EH .
MAYO CLINIC PROCEEDINGS, 1986, 61 (09) :697-705
[19]  
SOONG SJ, 1998, CUTANEOUS MELANOMA, P51
[20]   Management of patients with intermediate-thickness melanoma [J].
Urist, MM .
ANNUAL REVIEW OF MEDICINE, 1996, 47 :211-217